Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
FOLLISTIM vs A.P.L.
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Follistim (follitropin beta) is a recombinant follicle-stimulating hormone (FSH) that binds to FSH receptors on ovarian granulosa cells and testicular Sertoli cells, stimulating follicular development and steroidogenesis.
A. P. L. (Chorionic Gonadotropin) acts as a luteinizing hormone (LH) agonist, binding to LH receptors in the gonads to stimulate testosterone production in males and ovulation in females.
Ovulation induction in anovulatory women,Controlled ovarian hyperstimulation for assisted reproductive technologies,Spermatogenesis induction in men with hypogonadotropic hypogonadism
Induction of ovulation in anovulatory infertile women,Treatment of hypogonadism and cryptorchidism in males,Off-label: Assisted reproductive technology (ART) protocols
Subcutaneous: 75-300 IU once daily for 7-21 days, adjusted based on response. Intramuscular: 75-150 IU once daily for 7-21 days.
500-1000 mg every 4-6 hours, not to exceed 3000 mg/day in adults.
The terminal elimination half-life ranges from 16 to 24 hours (mean ~19 hours) following subcutaneous administration. In patients with renal impairment, half-life may be prolonged, necessitating dose adjustment.
Terminal elimination half-life: 2.5–3.5 hours (elimination phase); clinical context: requires repeated dosing for sustained effect.
Follitropin beta is metabolized primarily in the liver and kidneys via proteolytic degradation; no specific cytochrome P450 involvement.
Primarily via glucuronidation (60%) and sulfation (35%) in the liver, with a minor portion (5%) via CYP2E1 oxidation to the toxic metabolite N-acetyl-p-benzoquinone imine (NAPQI), which is normally detoxified by glutathione.
Primarily renal; approximately 70% of the dose is excreted unchanged in urine. A minor fraction (less than 5%) appears in feces via biliary elimination. The remainder is metabolized via hepatic pathways to inactive metabolites.
Renal: 10% unchanged; hepatic metabolism to inactive metabolites excreted in urine and feces (90% combined).
Approximately 45-50% bound, primarily to albumin and to a lesser extent to alpha-2-macroglobulin.
80–90% bound to sex hormone-binding globulin (SHBG) and albumin.
Volume of distribution is approximately 0.3 L/kg (range 0.2-0.4 L/kg), consistent with distribution largely into extracellular fluid.
0.5–0.9 L/kg, indicating moderate tissue distribution (primarily gonads and liver).
Subcutaneous: Approximately 77% (compared to intravenous administration). Intramuscular: approximately 75%. Not available for other routes.
IM: 100%; Subcutaneous: ~80% (relative to IM); Oral: <5% (not clinically used).
No specific guidelines; use caution in severe impairment (e GFR <30 m L/min/1.73m²) due to limited data.
No specific adjustment required for mild to moderate renal impairment. In severe renal impairment (Cr Cl < 10 m L/min), extend dosing interval to every 8 hours.
No specific guidelines; use caution in severe hepatic impairment (Child-Pugh C) due to limited data.
Caution in severe hepatic impairment; consider dose reduction or extended interval. Avoid use in active liver disease.
Not FDA-approved for pediatric use; off-label doses: 75-150 IU subcutaneously daily, weight-based titration (1.5-2.25 IU/kg/day) for adolescent males with hypogonadotropic hypogonadism.
Weight-based: 10-15 mg/kg every 4-6 hours, not to exceed 5 doses per day or 75 mg/kg/day.
Not indicated for geriatric use; no dose adjustment recommended, but limited data in elderly >65 years.
No specific dose adjustment, but consider renal and hepatic function and avoid exceeding 3000 mg/day.
Follistim should be used only by physicians experienced in infertility treatment. It may cause ovarian hyperstimulation syndrome (OHSS) and multiple gestations. Serious pulmonary and vascular events have been reported.
No black box warning.
Ovarian hyperstimulation syndrome (OHSS) can be severe; monitor ovarian response. Risk of multiple gestation and ectopic pregnancy. Ovarian torsion and adnexal torsion reported. Thromboembolic events. Ovarian enlargement may occur. Patients with porphyria may exacerbate condition.
May cause fluid retention, ovarian hyperstimulation syndrome (OHSS) in females,Increased risk of thromboembolic events,Precocious puberty in males,Not for use in prepubertal children unless for cryptorchidism
Hypersensitivity to follitropin beta or any component. High levels of FSH indicating primary ovarian failure. Uncontrolled thyroid or adrenal dysfunction. Ovarian cyst or enlargement unrelated to PCOS. Pregnancy. Sex hormone-dependent tumors (e.g., ovarian, breast, uterine, pituitary). Abnormal genital bleeding of undetermined origin.
Hypersensitivity to chorionic gonadotropin or any component,Precocious puberty (in males),Prostatic carcinoma or other androgen-dependent neoplasms,Ovarian cyst or enlargement not due to polycystic ovary syndrome
No specific food interactions are documented. Grapefruit and grapefruit juice may potentially affect hormone metabolism, though not established for Follistim; advise patients to maintain a consistent diet and report unusual changes.
No known food interactions. Avoid alcohol during treatment.
FOLLISTIM (follitropin beta) is classified as Pregnancy Category X. There is no indication for use during pregnancy. Animal studies have shown evidence of fetal abnormalities, and use is contraindicated in pregnant women. In the first trimester, exposure may cause fetal harm; however, no well-controlled studies exist. The drug is not used after conception, as its sole indication is for ovulation induction and controlled ovarian stimulation prior to assisted reproductive technologies.
A. P. L. (chorionic gonadotropin) is not expected to increase the risk of congenital anomalies when used in early pregnancy. However, use in the first trimester is generally avoided unless indicated for specific conditions. Data are limited; no increased fetal risk reported in inadvertent exposures. Second and third trimester use is not associated with teratogenicity but may increase risk of multiple gestation (if used for ovulation induction).
FOLLISTIM is not recommended for use during breastfeeding. It is not known whether follitropin beta is excreted in human milk. Given the potential for serious adverse reactions in nursing infants, a decision should be made to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother. No M/P ratio is available.
Chorionic gonadotropin is not detected in breast milk following maternal administration. M/P ratio not established. Considered compatible with breastfeeding; no adverse effects on infant reported. Use with caution if high doses are administered.
There are no recommended dosing adjustments for FOLLISTIM during pregnancy because the drug is contraindicated and not used in pregnancy. Pregnancy results from treatment, at which point FOLLISTIM is discontinued. No pharmacokinetic changes are studied in pregnancy as it is not administered to pregnant women.
No pharmacokinetic studies in pregnancy. Dose adjustments are not typically required during pregnancy for standard indications. For ovulation induction, dosing is based on follicular development. In first trimester for luteal support, standard doses are used. No evidence of altered clearance or need for dose changes due to pregnancy.
Follistim (follitropin beta) is a recombinant FSH used for ovulation induction and controlled ovarian stimulation. Monitor estradiol levels and follicular growth via ultrasound to adjust dosing. Risk of ovarian hyperstimulation syndrome (OHSS) increases with high estradiol (>3000 pg/m L) and multiple follicles. Do not use in primary ovarian failure, uncontrolled thyroid/adrenal disorders, or sex hormone-dependent tumors. For subcutaneous administration; rotate injection sites.
A. P. L. (chorionic gonadotropin) is used to trigger ovulation in assisted reproductive technology. Administer when follicles are mature (≥18 mm). Risk of ovarian hyperstimulation syndrome (OHSS) increases with higher doses. Monitor for abdominal pain, distension, and weight gain. Use caution in patients with prior thromboembolism.
Follistim is injected subcutaneously exactly as prescribed; do not skip or change dose without talking to your doctor.,You will need regular blood tests and ultrasounds to monitor your response and adjust treatment.,Common side effects include injection site reactions, headache, nausea, and bloating.,Contact your doctor immediately if you experience severe pelvic pain, sudden weight gain, or difficulty breathing, which could indicate ovarian hyperstimulation syndrome (OHSS).,Follistim increases the chance of multiple pregnancy (twins, triplets).,Store vials in the refrigerator, not frozen, and protect from light. Do not use if solution is cloudy or contains particles.
This medication is given as an injection exactly as prescribed to trigger ovulation.,A single dose is usually sufficient; follow your doctor's timing instructions closely.,Common side effects include headache, fatigue, and injection site reactions.,Seek immediate medical help if you experience severe pelvic pain, nausea, vomiting, or sudden weight gain (signs of OHSS).,Report symptoms of blood clots: leg pain, chest pain, or shortness of breath.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about FOLLISTIM vs A.P.L., answered by our medical review team.
FOLLISTIM is a Gonadotropin that works by Follistim (follitropin beta) is a recombinant follicle-stimulating hormone (FSH) that binds to FSH receptors on ovarian granulosa cells and testicular Sertoli cells, stimulating follicular development and steroidogenesis.. A.P.L. is a Gonadotropin that works by A. P. L. (Chorionic Gonadotropin) acts as a luteinizing hormone (LH) agonist, binding to LH receptors in the gonads to stimulate testosterone production in males and ovulation in females.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between FOLLISTIM and A.P.L. depend on the specific clinical indication. These are both Gonadotropin agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of FOLLISTIM is: Subcutaneous: 75-300 IU once daily for 7-21 days, adjusted based on response. Intramuscular: 75-150 IU once daily for 7-21 days.. The standard adult dose of A.P.L. is: 500-1000 mg every 4-6 hours, not to exceed 3000 mg/day in adults.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between FOLLISTIM and A.P.L. in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. FOLLISTIM is classified as Category C. FOLLISTIM (follitropin beta) is classified as Pregnancy Category X. There is no indication for use during pregnancy. Animal studies have shown evidence of fetal abnormalities, and . A.P.L. is classified as Category C. A.P.L. (chorionic gonadotropin) is not expected to increase the risk of congenital anomalies when used in early pregnancy. However, use in the first trimester is generally avoided . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.